Citi Just Made Zoetis Its Top Pick With a Buy Rating: Is the Pet Economy Boom the Best Trade of 2026?

Citi initiated Zoetis (NYSE:ZTS) at Buy with a $145 price target and named it its top pick in animal health, implying meaningful upside from the recent ~$121 share price. The firm highlighted pet humanization, a large osteoarthritis pain market, and an upside 90-day catalyst watch tied to Solensia returning to growth in fiscal 2026. Offset by risks, Zoetis still faces a 23% decline in China revenue in Q4 2025, FX headwinds, and tariff uncertainty.

Analysis

ZTS is the cleanest way to express a structural consumer upgrade trend in animal health, but the more important read-through is that pricing power is being tested against an innovation-cycle reset. The near-term setup is less about broad pet demand and more about whether new therapies can re-accelerate category growth after a visible slowdown in existing biologics; if that inflects, the market will likely re-rate ZTS before revenue acceleration is fully visible in reported numbers.

The competitive implication is that this is not just a ZTS story: a stronger read-through on OA pain adoption would force rivals and adjacent players to spend more aggressively on commercialization and pipeline differentiation, compressing margins across the group. ELAN and PAHC look like lower-quality beneficiaries only if investor appetite broadens into a basket trade; otherwise, capital should continue to concentrate in the asset with the best balance of brand, distribution, and pipeline optionality.

The key risk is timing mismatch. The stock can work on the catalyst watch if traders front-run fiscal 2026 growth, but the trade is vulnerable if U.S. momentum does not stabilize within the next 1-2 quarters; that would turn the thesis into a multi-quarter prove-it story. China weakness and FX matter less for valuation than they do for sentiment, because they can delay multiple expansion even if the underlying category remains intact.

Contrarianly, the market may already be underwriting too much of the long-duration pet-humanization narrative and not enough execution risk in new product launches. If the rollout cadence slips or competitive therapies gain share, the current setup becomes a low-teens earnings multiple with no catalyst, not a premium compounder. The better way to own the view is through event timing, not passive exposure.

Key Decisions for Investors

• Go long ZTS on weakness into the next 1-2 weeks, targeting a 6-10% upside re-rating toward the analyst target if Solensia stabilization language improves; risk is a 5-7% drawdown if channel checks stay soft.
• Buy ZTS Jan-2026 or Mar-2026 calls to express the fiscal 2026 growth inflection with defined downside; this fits a 3-5 month catalyst window and limits exposure to FX/tariff noise.
• Pair trade: long ZTS / short ELAN for the next 1-2 quarters to isolate best-in-class pipeline quality versus lower-conviction execution risk; the spread should widen if the market rewards clarity over optionality.
• If entering the sector basket, prefer ZTS over IDXX and PAHC; use the others only as smaller beta expressions because the alpha is in pipeline-led reacceleration, not broad animal-health enthusiasm.
• Set a tactical stop if the next update fails to show sequential improvement in U.S. mAb demand; that would invalidate the near-term catalyst and push the thesis out by at least two quarters.